| Q74578853 | A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion |
| Q36365851 | A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes |
| Q34021153 | A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma |
| Q28141612 | A new era for cancer immunotherapy based on the genes that encode cancer antigens |
| Q24307739 | A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma |
| Q28288235 | A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma |
| Q36365847 | A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene |
| Q24564781 | A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening |
| Q41254841 | A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes |
| Q38576508 | Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. |
| Q36914397 | Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen |
| Q39243052 | Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies |
| Q30310231 | Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy |
| Q73155785 | Binding and transport of melanoma-specific antigenic peptides by the transporter associated with antigen processing |
| Q35048637 | CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production |
| Q41459252 | Cancer vaccines based on the identification of genes encoding cancer regression antigens |
| Q33586656 | Cancer vaccines: novel approaches and new promise |
| Q36084122 | Cell-free tumor antigen peptide-based cancer vaccines |
| Q33822591 | Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression |
| Q33603062 | Clinical implications of the new biology in the development of melanoma vaccines |
| Q36853706 | Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100 |
| Q35215158 | Current advances in T-cell-based cancer immunotherapy |
| Q41202957 | Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens |
| Q41008997 | Cytotoxic T lymphocyte clone specific for autologous human hepatocellular carcinoma cell line SUHC-1. |
| Q40732047 | DNA vaccines for cancer therapy |
| Q36380718 | Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases |
| Q61046315 | Detection and quantification of CD8+ T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-?-elispot assay |
| Q30469600 | Direct identification of tumor-associated peptide antigens. |
| Q77317862 | Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response |
| Q35005930 | Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens |
| Q36983356 | Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines |
| Q37576033 | Exploiting the curative potential of adoptive T-cell therapy for cancer |
| Q35741270 | Fc receptors are required in passive and active immunity to melanoma |
| Q45888601 | Gene therapy for melanoma in humans |
| Q34187915 | Gene therapy: development of immunostimulatory treatments for cancer |
| Q41316114 | Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines |
| Q54979851 | Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer. |
| Q41090411 | Human tumor antigens are ready to fly. |
| Q33776127 | Human tumor antigens for cancer vaccine development |
| Q24678508 | Human tumor antigens recognized by T lymphocytes |
| Q41687574 | Human tumor antigens recognized by T-cells |
| Q37569023 | IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation |
| Q24647904 | Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes |
| Q24569553 | Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens |
| Q36367223 | Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35) |
| Q36376523 | Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma |
| Q33706946 | Immune and gene therapy for melanoma, and the immunobiology of melanoma |
| Q39057617 | Immune targets and neoantigens for cancer immunotherapy and precision medicine |
| Q41455932 | Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy |
| Q34074742 | Immunologic approaches to antigen discovery for cancer vaccines |
| Q33949211 | Immunophenotyping of melanomas for tyrosinase: implications for vaccine development |
| Q34573035 | Immunotherapy for melanoma |
| Q45868793 | Immunotherapy of Human Melanoma With Gene-Modified Tumor Cell Vaccines |
| Q33755576 | Impact of Human Leukocyte Antigen Loci and Haplotypes on Intestinal Acute Graft-versus-host Disease after Human Leukocyte Antigen-matched Sibling Peripheral Blood Stem Cell Transplantation |
| Q36365511 | Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein |
| Q35996832 | In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites |
| Q41915168 | Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells |
| Q34107773 | Melanoma peptide vaccines: from preclinical background to clinical trials |
| Q37110386 | Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells |
| Q81251217 | Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations |
| Q36160526 | Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints |
| Q34568992 | Peptide vaccines for cancer |
| Q34173622 | Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402 |
| Q28344557 | Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy |
| Q34253585 | Progress in human tumour immunology and immunotherapy |
| Q34570245 | Progress in the development of immunotherapy for the treatment of patients with cancer |
| Q42679025 | Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice |
| Q33770310 | Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries |
| Q36772676 | Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: a projected basis for immunotherapy |
| Q30305530 | Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy |
| Q37562613 | Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas |
| Q41642426 | Serological identification of human tumor antigens |
| Q38170497 | TCR repertoires of intratumoral T-cell subsets |
| Q38753386 | The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer |
| Q34956078 | The T-cell response in patients with cancer |
| Q36470749 | The next wave of recombinant and synthetic anticancer vaccines |
| Q34232543 | The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity |
| Q45880112 | The role of cytokines in cancer |
| Q33815374 | The role of endoplasmic reticulum-associated protein degradation in MHC class I antigen processing |
| Q35945206 | Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen |
| Q36184573 | Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy |
| Q24646800 | Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage |
| Q30469630 | Tumor antigens and tumor vaccines: peptides as immunogens |
| Q36438078 | Tumor antigens discovery: perspectives for cancer therapy |
| Q37360526 | Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. |
| Q37387673 | Tumor immunity and autoimmunity induced by immunization with homologous DNA |
| Q41455911 | Tumor recognition by the cellular immune system: new aspects of tumor immunology. |
| Q40849487 | Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications |
| Q37848203 | Tumour-associated antigens: considerations for their use in tumour immunotherapy. |
| Q37842937 | Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma |
| Q36660661 | Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c2j gene substituted for the wild-type tyrosinase allele: utilization in design of syngeneic immunotherapy models |
| Q36989720 | Update on vaccine development for renal cell cancer |
| Q36365832 | Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen |
| Q47614455 | Vitiligo. Therapeutic advances |
| Q39992502 | pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL |